Methods for treating cancer using soluble forms of PSGL-1 and fusion molecules thereof
US12195518B2 · kind B2 · utility
0Cited by
4References
16Claims
0Family size
Inventor
Key dates
| Filing date | Dec 29, 2022 |
| Grant date | Jan 14, 2025 |
| Priority date | — |
| Expiry date | Dec 29, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods of using soluble tandem selectin glycoprotein ligand (TSGL) and TSGL fusion proteins, such as TSGL-Ig, in combination with T cell activation therapies or an adoptive cell transfer (ACT) therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.